Visiongain Publishes Cancer Stem Cells Market Report 2020-2030

02 August 2020
Pharma

Visiongain has launched a new pharma report Cancer Stem Cells Market Report 2020-2030: Prospects by Mode of Action (Targeted CSCs, Stem Cell Based Cancer Therapy), Cancer Forms (Bladder Cancer, Breast Cancer, Brain Cancer, Blood Cancer, Others), and Geography.

The global cancer stem cells market is projected to grow at a lucrative CAGR of ~xx% and anticipated to surpass USD xx million by 2030.

The increasing prevalence of cancer worldwide encourages vendors to develop novel stem cell therapies for cancer. During the forecast period, the market is expected to witness the launch of several drugs. Numerous cancer stem cell vendors are developing oral drugs to inhibit cancer stemness pathways by targeting signal transducer and activator of transcription 3 (STAT 3) to treat pancreatic cancer.

Many of these cancer stem cell therapies are currently undergoing clinical trials and are in Phase III which are expected to launch during the forecast period. It is anticipated that the strong drug development pipeline of novel stem cell therapies for cancer will drive the growth of the global cancer stem cell market.

One of the key trends influencing cancer stem cell growth is the availability of stem cell markers in the identification of cancer stem cells. Cervical cancer is one of the most frequent causes of death among women population. The heterogeneity of cervical carcinoma makes it challenging to classify cancer stem cells. The development of stem cell markers, however, has allowed the detection of stem cells for cancer in different types of cancer such as cervical cancer & breast cancer. The introduction of stem cell markers is expected to increase the number of different types of cancer to be detected and diagnosed. This will result in increased demand for cancer stem cell therapeutics.

Regulatory challenges related to the approval and use of stem cell therapies, however, are projected to restrain the market growth. Furthermore, it is anticipated that certain manufacturing & pharmacological problems associated with this development of cell therapy will slow the market progression over the forecast period.

In the year 2018, breast cancer dominated the global cancer stem cells market owing to its rising prevalence & availability of large numbers of stem cell therapeutics. Also, the fact that autologous transplant has taken chemotherapy to the next level is likely to add to the segment's development. Also, it has been found that stem cell therapies were effective in the battle against cardiotoxicity observed in survivors.

Due to the presence of a significant number of organizations involved in conducting stem cell therapy-related R&D activities, North America dominated the global stem cells market. The growing funding from public and private institutions coupled with growing industry attention on stem cell research is anticipated to boost the cancer stem cell market in the North American region over the forecast period.

Furthermore, Asia Pacific cancer stem cells market is anticipated to offer lucrative opportunities for revenue generation due to growing focus on research & development of stem cells, rising grants to research communities to accelerate scientific research, growing patient pool, rising healthcare expenditure and high clinical unmet needs in the region.

Some of the major players operating in this industry are AbbVie, Inc., Allosource, Anterogen Co., Ltd., Bionomics, Biotime, INC., Holostem Terapie Avanzate Srl, Irvine Scientific, JCR Pharmaceuticals Co., Ltd., LONZA, MacroGenics, Inc., Medipost Co., Ltd, Merck KGaA, Miltenyi Biotec, Nuvasive, Inc., ONCOMED Pharmaceuticals INC, Osiris Therapeutics, Inc., Pharmicell Co., Ltd., PromoCell GmbH, RTI Surgical, Inc., Sino Biological Inc among other prominent players.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Checkpoint Inhibitors for Treating Cancer Market Report 2021-2031

We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

29 July 2021

Read

Visiongain Publishes Direct-to-Patient Market Report 2021-2031

Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.

21 July 2021

Read

Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031

Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.

20 July 2021

Read

Visiongain Publishes Pharma Contract Sales Market Report 2021-2031

Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.

14 July 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever